A clinical trial comparing two treatments for postmenopausal vaginal discomfort – low-dose vaginal estrogen and a vaginal moisturizer – to placebo treatments found that both produced symptom improvements similar to those associated with the placebos after 12 weeks of treatment. The authors note that better understanding of the causes of postmenopausal symptoms could lead to more effective treatment options for this bothersome problem.
“The fact that all three treatments – vaginal estradiol tablets, a vaginal moisturizer and the gel we used as a placebo – were able to reduce symptoms is great news for women, since it means that regular use of any of these treatments is likely to have benefit, whether the cost is $20 or $200,” says Caroline Mitchell, MD, of the Massachusetts General Hospital (MGH) Department of Obstetrics and Gynecology, corresponding author of the report published online in JAMA Internal Medicine. “The significant impact of vaginal discomfort on the lives of women is reflected by how quickly we were able to enroll more than 300 participants – in less than a year. Women are desperate for some kind of intervention for these symptoms.”
The authors, from seven research centers across the country, note that symptoms such as vaginal dryness, itching and pain during sexual intercourse affect around half of postmenopausal women and can have negative quality-of-life effects similar to those of chronic conditions like arthritis or irritable bowel syndrome. But more than half of affected women use no medical treatments. Available nonprescription products, such as vaginal lubricants and moisturizers, can be messy; and prescription hormonal treatments in the form of creams, vaginal tablets and oral pills can be expensive and may raise concerns about safety.
The current study was designed to assess the effectiveness of the two most commonly recommended treatments – low-dose estrogen vaginal tablets and a nonhormonal vaginal moisturizer. At two clinical research sites – Kaiser Permanente Washington Health Research Institute in Seattle and the University of Minnesota in Minneapolis – the study enrolled 302 women, most between the ages of 55 and 64, who reported moderate to severe symptoms of vaginal itching, dryness, irritation or pain with sexual activity.
Participants were randomly divided into three groups -- one receiving a low-dose vaginal estrogen tablet and a placebo vaginal gel, one receiving a placebo vaginal tablet and the nonprescription vaginal moisturizer, and one receiving both placebo tablets and placebo gel. Participants were instructed to administer the vaginal tablet once a day for 2 weeks and then twice a week for the remaining 10 weeks of the study period. The moisturizing gels were to be applied every three days throughout the study period. Neither participants nor study staff knew to which group individual participants were assigned.
At the end of the study period all three groups had similar decreases in the severity of their most bothersome symptom. A similar proportion of women in each group had at least a 50 percent decrease in overall symptom severity, which probably represents a clinically noticeable improvement. Improvement in sexual function and overall treatment satisfaction were also similar across all three groups. There was a significantly higher positive response to the question, “Did you have a meaningful benefit from the treatment?” among those receiving the vaginal estrogen tablet than among those receiving the two placebos.
Mitchell notes that, while most studies of treatments for vaginal discomfort show a significant placebo effect, the size of the response to placebo treatments in this trial was surprising. “It’s hard to say whether the properties of this particular placebo gel are responsible, but our results suggest that regular use of any one of these products may be helpful,” she says. “During the 12 weeks of the trial, more than 90 percent of women used the medication regularly, but prior studies suggest that many women do not continue use of this type of treatment beyond 6 months. A remaining question is whether women find the benefits of the treatment worthwhile enough to continue regular use.” Mitchell is an assistant professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School.
Co-author Susan Reed, MD, of the University of Washington Department of Obstetrics and Gynecology adds, “It was notable that the overwhelming majority of women in our study were bothered by pain with sexual activity and earnestly wanted to help find a treatment for the many women bothered by this problem. More couples are remaining sexually intimate despite aging, and better therapies for vaginal discomfort need to be developed.”
The senior author of the JAMA Internal Medicine report is Katherine A. Guthrie, PhD, of the Fred Hutchinson Cancer Research Center in Seattle. Additional co-authors are Susan Diem, MD, and Kristine Ensrud, MD, University of Minnesota; Joseph Larson, MS, Fred Hutchinson Cancer Research Center; Katherine Newton, PhD, Kaiser Permanente Washington Health Research Institute; Andrea LaCroix, PhD, University of California at San Diego School of Medicine, and Bette Caan, DrPH, Kaiser Permanente of Northern California. The study was funded by National Institute on Aging grant 5RO1 AG048209.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $900 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."